Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats
- PMID: 17169538
- DOI: 10.1016/j.ejps.2006.10.009
Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats
Abstract
The purpose of the study was to adjust the individual maintenance dose of warfarin with a simple approach based on indirect pharmacodynamic model (IDR). Based on the distinct pharmacokinetic and pharmacodynamic features of warfarin, the relationship between the maintenance dose and the steady-state anticoagulation effect was simplified and an approach for the maintenance dose adjustment was proposed. According to the steady-state anticoagulation effect before and after multiple doses (0.1 mg kg(-1)day(-1)), the optimal maintenance doses were predicted for the target anticoagulation effect (INR(target)=2.5), then the actual anticoagulation effect (prothrombin times, PT) on the 6th (8 pm)\8th (8 am)\10th (2 pm) day after dose adjustment according the present method was compared with the target effects with a view of determination the feasibility and accuracy of the proposed approach. The proposed method was also used to adjust warfarin maintenance doses in the presence of metabolism inhibitor metronidazole. The results suggested that the proposed approach could appropriately achieve the target international normalized ratio (INR(target)) when warfarin used alone or in combination with metronidazole, the actual INR values of three days were 2.69+/-0.18 and 2.52+/-0.22 (mean+/-S.D.), respectively. The method provided a relatively simple and accurate strategy for warfarin maintenance dose adjustment.
Similar articles
-
Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.Am J Med. 2005 Feb;118(2):137-42. doi: 10.1016/j.amjmed.2004.07.053. Am J Med. 2005. PMID: 15694897 Clinical Trial.
-
Absence of a pharmacokinetic interaction between etanercept and warfarin.J Clin Pharmacol. 2004 May;44(5):543-50. doi: 10.1177/0091270004264164. J Clin Pharmacol. 2004. PMID: 15102876
-
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.Clin Pharmacol Ther. 2000 Dec;68(6):626-36. doi: 10.1067/mcp.2000.112244. Clin Pharmacol Ther. 2000. PMID: 11180023 Clinical Trial.
-
An algorithm for managing warfarin resistance.Cleve Clin J Med. 2009 Dec;76(12):724-30. doi: 10.3949/ccjm.76a.09062. Cleve Clin J Med. 2009. PMID: 19952297 Review.
-
Self-management of anticoagulation.Expert Rev Cardiovasc Ther. 2008 Aug;6(7):979-85. doi: 10.1586/14779072.6.7.979. Expert Rev Cardiovasc Ther. 2008. PMID: 18666848 Review.
Cited by
-
Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins.Molecules. 2010 Jan 12;15(1):270-9. doi: 10.3390/molecules15010270. Molecules. 2010. PMID: 20110890 Free PMC article.
-
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.PLoS One. 2011;6(11):e27808. doi: 10.1371/journal.pone.0027808. Epub 2011 Nov 16. PLoS One. 2011. PMID: 22114699 Free PMC article.
-
Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.J Am Soc Nephrol. 2011 Oct;22(10):1856-62. doi: 10.1681/ASN.2010101110. Epub 2011 Sep 1. J Am Soc Nephrol. 2011. PMID: 21885669 Free PMC article.
-
A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):853-869. doi: 10.1002/psp4.13123. Epub 2024 Mar 15. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38487942 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical